All filters
Slidesets
Case based debate: Is HCC increased with DAA therapy? Pro stance- Douglas Dieterich, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Antifibrotics and fatty liver drugs in the pipeline- Sanjay Bhagani, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Hepatic steatosis AND Lipid proFile evolution After Hepatitis C treatment in HCV/HIV coinfected patients- J. Méndez
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Treatment of cirrhotic HCV/HIV co-infected patients with DAAs- R. Sarmento e Castro
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Regression of liver fibrosis in patients with chronic hepatitis C treated with direct acting anti-viral (DAA) therapy in the country of Georgia- E. Dolmazashvili
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
HCV elimination program in Georgia: Successes and challenges- Nikoloz Chkhartishvili, MD, MS, PhD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
What challenges remain in viral hepatitis- Jürgen Rockstroh, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
NASH and NAFLD in HIV: same or different? - Mariana Machado, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017